Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of EXCL-100 (Pirfenidone SR) vs Esbriet in Healthy Volunteers
NCT05428150Phase 1Completed
- Sponsor
- Excalibur Pharmaceuticals, Inc.
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pirfenidone in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Excalibur Pharmaceuticals, Inc. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity. Started Aug 2022; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05428150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428150.